Barbara,
Please ask Dr Pegram what he thinks of the Tykerb+ Herceptin combo for advanced breast cancer based in particular on the very positive comments of the phase 2 trials in the neo adjuvant setting that came out after the SABCS in december 2006.
Also does he believe adding Tykerb after becoming resistant to Herceptin is better or not than starting with the combo?
Finally if the finding in mice that Tykerb inhibit IGF-I (which is involved in one of the way resistance to Herceptin builds up) is assumed to be true in humans what would that mean for the combo & for keeping Herceptin even after progression?
Refs:
http://www.breastcancerupdate.com/do...8_06_Chang.mp3
http://mct.aacrjournals.org/cgi/con...bstract/6/2/667
Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling
P.S.
If that is not too much, ask him for an update on the comments he made more than one year ago that ongoing trials of Fulvestrant+ Herceptin could be important in preventing reccurencies in ER+ tumours caused by crosstalk between Her-2 & ER